Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03832582
Other study ID # P1700905J
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date May 1, 2019
Est. completion date December 31, 2024

Study information

Verified date September 2018
Source Assistance Publique - Hôpitaux de Paris
Contact Olivier Milleron, MD
Phone 00 33 1 40 25 68 16
Email olivier.milleron-ext@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The relationship between the presence of a partial thrombus and aortic dilation after type B dissection has recently been reported. The originality lies in the idea of imaging thrombus activity to predict dilation after type B dissection. The innovative character is based on the use of annexin scintigraphy.


Description:

To establish the proof of concept in humans of the link between the intensity of 99mTc-annexin V-128 binding in the descending thoracic aorta and the progression of aortic diameter in patients with type B aortic dissection.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 83
Est. completion date December 31, 2024
Est. primary completion date May 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- patient whose age is = 18 years old

- any patient seen more than 6 months and less than 5 years after a dissection involving the descending aorta at Bichat Hospital, whether it is a dissection of the descending aorta alone or a dissection of the ascending aorta extended to the descending aorta

- dissection of the uncomplicated descending thoracic aorta: not requiring surgery or stent implantation within the first 6 months after acute dissection

- effective contraception for women of childbearing age

Exclusion Criteria:

- scheduled procedure for dissection of the descending aorta

- contraindication to aortic CT with injection of contrast media: renal failure with creatinine clearance <30 ml/min or creatinine >200 µmol/l; allergy to contrast media

- history of surgery or stent implantation in the descending thoracic aorta

- pregnant or breastfeeding women

- patient under guardianship or trusteeship

- non affiliation to social security or CMU (beneficiary or assignee)

- patient refusal to participate in the study

Study Design


Related Conditions & MeSH terms

  • Chronic Dissection of Thoracic Aorta (Disorder)

Intervention

Drug:
Annexin
All patients will undergo a 99mTc-annexin V-128 scintigraphy (SPECT)

Locations

Country Name City State
France Service de Cardiologie - Hôpital Bichat Claude Bernard Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Correlation between the rate of expansion of the aortic diameter and the intensity of attachment of the annexin by the aortic wall descending Pearson correlation coefficient between the rate of expansion of the aortic diameter measured by CT (at 6 months, 18 months and 30 months) in mm/year (at the site of maximum expansion) and the intensity of attachment of the annexin by the aortic wall descending in scintigraphy. 30 months
Secondary Determination of the optimal threshold for annexin fixation to predict the evolution of aortic dilation (< 2 mm/year, >=2mm year) using ROC curve. Determination of the optimal threshold for annexin fixation to predict the evolution of aortic dilation (< 2 mm/year, >=2mm year) using ROC curve. The cut-off point will be defined by the Youden index. 30 months
Secondary Blood level of fibrinolysis markers (D dimers, plasmin/anti-plasmin complexes) Blood level of fibrinolysis markers (D dimers, plasmin/anti-plasmin complexes) 30 months
Secondary Blood level of thrombus procoagulant activity markers (circulating P-selectin and thrombin/anti-thrombin complexes) Blood level of thrombus procoagulant activity markers (circulating P-selectin and thrombin/anti-thrombin complexes) 30 months
Secondary Morphological characteristics of the wall thrombus Morphological characteristics of the wall thrombus: no thrombus of the false lumen, partial thrombosis or total thrombosis of the false lumen. 30 months
Secondary Determination of potential predictive clinical factors of aortic dilation rate Determination of potential predictive clinical factors of aortic dilation rate: age, blood pressure, heart rate, sex, history of dissection, etiology (Marfan or no Marfan) 30 months
Secondary Determination of potential predictive SPECT factors of aortic dilation rate Determination of potential predictive SPECT factors of aortic dilation rate: anormal annexin binding, ratio of annexin binding (TBR = Target-to-Background Ratio) 30 months
Secondary Determination of potential predictive biological factors of aortic dilation rate Determination of potential predictive biological factors (C-Reactive Protein) of aortic dilation rate 30 months
Secondary Determination of potential predictive morphological factors of aortic dilation rate Determination of potential predictive morphological factors of aortic dilation rate: no thrombus, partial thrombosis or total thrombosis. 30 months
Secondary Number of cardiovascular events Number of cardiovascular events: cardiovascular death, dissection complications (including aortic rupture, malperfusion, emboli), aortic surgery. 30 months
Secondary Evaluation of the tolerance of the annexin scintigraphy by collecting side effects occurence Tolerance of the annexin scintigraphy will be assessed using a questionnaire during a phone call at day 3 to ask the patients about side effects occurrence. 3 days